(NASDAQ: ATYR) Atyr Pharma's forecast annual revenue growth rate of 595.02% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.58%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.72%.
Atyr Pharma's revenue in 2025 is $235,000.On average, 1 Wall Street analysts forecast ATYR's revenue for 2025 to be $1,057,674,328, with the lowest ATYR revenue forecast at $1,057,674,328, and the highest ATYR revenue forecast at $1,057,674,328. On average, 2 Wall Street analysts forecast ATYR's revenue for 2026 to be $1,661,639,947, with the lowest ATYR revenue forecast at $1,057,674,328, and the highest ATYR revenue forecast at $2,265,605,565.
In 2027, ATYR is forecast to generate $7,107,067,831 in revenue, with the lowest revenue forecast at $1,678,848,140 and the highest revenue forecast at $13,741,372,026.